5 Strategic Interview Questions for a Novartis CHRO Candidate
Candidate background: Former CHRO at Dr. Reddy's Laboratories and Cipla Target role: CHRO, Novartis
I would approach this as a business transformation and strategic leadership interview, rather than a conventional HR interview.
The critical distinction is that Cipla and Dr. Reddy's have substantial generics businesses, while Novartis is an innovative-medicines company where R&D productivity, patents, specialty therapies, global talent and scientific innovation are central to value creation.
The candidate's experience in two major pharmaceutical companies is relevant, but it does not automatically demonstrate readiness for Novartis.
### The five questions I would ask
1. Business acumen: Did HR anticipate the erosion of profitability?
"Both Cipla and Dr. Reddy's experienced significant pressure on North American revenue and profitability, even as their India businesses continued growing. During your tenure, how did you anticipate changes in product economics, and what specific workforce, leadership or capability decisions did you make before the financial impact became visible?"
Probe:
Ask for one decision supported by financial modelling, its implementation date, and the measurable impact on productivity, costs or profitability.
What this tests: Whether the candidate understands P&L dynamics and leads proactively rather than responding to restructuring demands.
2. Strategic transition: Can a generics CHRO lead an innovation-driven organisation?
"Novartis competes through innovative medicines, scientific discovery and differentiated therapies rather than primarily through generic-drug volume and cost efficiency. What would you fundamentally change in your talent strategy, rewards architecture, performance management and succession planning to make that transition?"
Probe:
"How would you attract and retain exceptional scientists, clinical-development leaders and digital-health talent when their contribution may take five to ten years to become commercially visible?"
What this tests: Understanding of scientific talent, long-cycle innovation, differentiated rewards and organisational capabilities.
3. M&A integration: Has the candidate actually created value after acquisitions?
"Both Cipla and Dr. Reddy's pursued acquisitions and portfolio diversification. Tell me about an acquisition, divestment or strategic partnership during your tenure where you personally led the people-integration agenda. How did you retain critical talent, resolve cultural differences and demonstrate that HR integration contributed to the business case?"
Probe:
Ask for critical-talent retention at 12 and 24 months, leadership attrition, integration costs, time to productivity and the original synergy targets.
What this tests: Post-merger integration, cultural due diligence, executive decision-making and financial accountability.
A strong candidate should distinguish the acquisition's overall performance from the portion attributable to their own actions.
4. Regulatory risk: Is quality culture genuinely an HR responsibility?
"Pharmaceutical profitability is highly vulnerable to manufacturing disruptions, FDA observations, quality failures and supply interruptions. What have you done as CHRO to ensure that leadership incentives, production targets, talent decisions and employee voice strengthen quality and patient safety rather than undermine them?"
Probe:
"Describe an instance when you challenged a business leader or changed an incentive arrangement because commercial priorities were creating unacceptable quality or compliance risks."
What this tests: Integrity, courage, quality culture, speak-up mechanisms and governance.
For Novartis, this is especially important because patient safety and regulatory credibility cannot be subordinated to quarterly earnings.
5. Future readiness: Can the candidate redesign the workforce for AI-driven pharmaceutical innovation?
"Imagine you join Novartis and are asked to improve R&D productivity, accelerate AI adoption and build critical capabilities without proportionately increasing headcount. What would your first 180 days look like, and what three business-linked metrics would demonstrate that your people strategy is working?"
Probe:
Ask how the candidate would balance automation with scientific judgment, reskilling, workforce redeployment and employee trust.
What this tests: Enterprise workforce strategy, AI literacy, organisational design and execution discipline.
These dimensions align with Novartis's published strategic priorities around innovative medicines, operational excellence, scientific talent, culture and AI. SEC +1
One final interviewing principle: Do not attribute Cipla's or Dr. Reddy's 2026 performance to this candidate without first establishing their exact tenure, scope of responsibility and decision rights. Ask them to explain what changed during their leadership, what they personally initiated, and what measurable results persisted after they left.
A strong Novartis CHRO candidate should demonstrate not merely that they have led HR in pharmaceuticals, but that they can translate scientific and commercial strategy into organisational capabilities that create long-term enterprise value.
Comments
Post a Comment